PATENT CLAIM ANALYSIS

Application Number: 15747867
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-01
Patent Classification: ["514", "250000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Claim (Index 1):
A compound of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein:\n L is independently selected from \n is an optional bond; Q is independently selected from O, NH, and CH 2 ; Y is independently selected from N and CR 7 ; ring A is independently selected from R 1  and R 2  are independently selected from H, halogen, C 1-4  alkyl substituted with 0-4 R e , OR b , and C 3-5  cycloalkyl substituted with 1-4 R 6 ; R 3  is independently selected from H, C 1-4  alkyl substituted with 1-5 R 5 , C 2-4  alkenyl substituted with 1-5 R 5 , C 2-4  alkynyl substituted with 1-5 R 5 , CN, \u2014(CH 2 ) n \u2014OR b , \u2014(CH 2 ) n \u2014NR a R a , \u2014(CH 2 ) n \u2014C(\u2550O)R b , \u2014(CH 2 ) n \u2014C(\u2550O)OR b , \u2014(CH 2 ) n \u2014NR a C(\u2550O)OR b , \u2014(CH 2 ) n \u2014NR a C(\u2550O)R b , \u2014(CH 2 ) n \u2014NR a C(N\u2014CN)NR a R a , \u2014(CH 2 ) n \u2014NR a C(NH)NR a R a , \u2014(CH 2 ) n \u2014N\u2550CR b NR a R a , \u2014(CH 2 ) n \u2014NR a C(\u2550O)NR a R a , \u2014(CH 2 ) n \u2014C(\u2550O)NR a R a , \u2014(CH 2 ) n \u2014NR a C(\u2550S)NR a C(\u2550O)R b , \u2014(CH 2 ) n \u2014S(\u2550O) p R c , \u2014(CH 2 ) n \u2014S(\u2550O) p NR a R a , \u2014(CH 2 ) n \u2014NR a S(\u2550O) p NR a R a , \u2014(CH 2 ) n \u2014NR a S(\u2550O) p R c , \u2014(CR d R d ) n \u2014C 3-10  carbocyclyl substituted with 1-5 R 5 , and \u2014(CR d R d ) n -4- to 10-membered heterocyclyl substituted with 1-5 R 5 ; optionally, two adjacent R 3  groups on the carbocyclyl and heterocyclyl may form a ring substituted with 1-5 R 5 ; R 3a  is independently selected from H and C 1-4 alkyl; alternatively, R 3a  and R 3  are taken together to form a heterocyclic ring comprising carbon atoms and 1-3 heteroatoms selected from O, NR 3b , S, wherein the heterocyclic ring is substituted with R 3c ; R 3b  is independently selected from H, C 1-4  alkyl substituted with 1-5 R 5 , \u2014(CH 2 ) n \u2014C(\u2550O)R b , \u2014(CH 2 ) n \u2014C(\u2550O)OR b , \u2014(CH 2 ) n \u2014C(\u2550O)NR a R a , \u2014(CH 2 ) n \u2014NHC(\u2550O)OR b , \u2014(CH 2 ) n \u2014S(\u2550O) p R c , \u2014(CH 2 ) n \u2014S(\u2550O) p NR a R a , \u2014(CR d R d ) n \u2014C 3-10  carbocyclyl substituted with 1-5 R 5 , and \u2014(CR d R d ) n -4- to 10-membered heterocyclyl substituted with 1-5 R 5 ; R 3c  is independently selected from H, NO 2 , \u2550O, halogen, C 1-4  alkyl substituted with 1-5 R 5 , C 2-4  alkenyl substituted with 1-5 R 5 , C 2-4  alkynyl substituted with 1-5 R 5 , CN, \u2014(CH 2 ) n \u2014OR b , \u2014(CH 2 ) n \u2014NR a R a , \u2014(CH 2 ) n \u2014C(\u2550O)R b , \u2014(CH 2 ) n \u2014C(\u2550O)OR b , \u2014(CH 2 ) n \u2014NR a C(\u2550O)OR b , \u2014(CH 2 ) n \u2014NR a C(\u2550O)R b , \u2014(CH 2 ) n \u2014NR a C(N\u2014CN)NR a R a , \u2014(CH 2 ) n \u2014NR a C(NH)NR a R a , \u2014(CH 2 ) n \u2014N\u2550CR b NR a R a , \u2014(CH 2 ) n \u2014NR a C(\u2550O)NR a R a , \u2014(CH 2 ) n \u2014C(\u2550O)NR a R a , \u2014(CH 2 ) n \u2014NR a C(\u2550S)NR a C(\u2550O)R b , \u2014(CH 2 ) n \u2014S(\u2550O) p R c , \u2014(CH 2 ) n \u2014S(\u2550O) p NR a R a , \u2014(CH 2 ) n \u2014NR a S(\u2550O) p NR a R a , \u2014(CH 2 ) n \u2014NR a S(\u2550O) p R c , \u2014(CR d R d ) n \u2014C 3-10  carbocyclyl substituted with 1-5 R 5 , and \u2014(CR d R d ) n -4- to 10-membered heterocyclyl substituted with 1-5 R 5 ; R 4  is independently selected from H, halogen, CN, \u2014(CH 2 ) n NR a R a , C 1-6  alkyl substituted with 1-5 R 10 , \u2014(CH 2 ) n OR b , \u2014(CH 2 ) n C(\u2550O)R b , \u2014(CH 2 ) n C(\u2550O)OR b , \u2014(CH 2 ) n \u2014NR a C(\u2550O)OR b , \u2014(CH 2 ) n \u2014NR a C(\u2550O)R b , \u2014(CH 2 ) n \u2014NR a C(N\u2014CN)NR a R a , \u2014(CH 2 ) n \u2014NR a C(NH)NR a R a , \u2014(CH 2 ) n \u2014N\u2550CR b NR a R a , \u2014(CH 2 ) n \u2014NR a C(\u2550O)NR a R a , \u2014(CH 2 ) n \u2014C(\u2550O)NR a R a , \u2014(CH 2 ) n \u2014NR a C(\u2550S)NR a C(\u2550O)R b , \u2014(CH 2 ) n \u2014S(\u2550O) p R c , \u2014(CH 2 ) n \u2014S(\u2550O) p NR a R a , \u2014(CH 2 ) n \u2014NR a S(\u2550O) p NR a R a , \u2014(CH 2 ) n \u2014NR a S(\u2550O) p R c , \u2014(CH 2 ) n -aryl substituted with 1-5 R 10 , \u2014(CH 2 ) n \u2014C 3-6  cycloalkyl substituted with 1-5 R 10 , and \u2014(CH 2 ) n -4-6 membered heterocyclyl substituted with 1-5 R 10 ; R 5 , at each occurrence, is independently selected from H, D, \u2014(CH 2 ) n \u2014OR b , \u2550O, \u2014(CH 2 ) n NH 2 , \u2014(CH 2 ) n CN, halogen, C 1-6  alkyl, \u2014(CH 2 ) n \u2014C(\u2550O)OR b , \u2014(CH 2 ) n \u2014OR b , \u2014(CH 2 ) n \u2014C 3-10  carbocyclyl substituted with 0-5 R e , \u2014(CH 2 ) n -4- to 10-membered heterocyclyl substituted with 0-5 R e , and \u2014O-4- to 10-membered heterocyclyl substituted with 0-5 R e ; R 6  is independently selected from H, OH, \u2550O, \u2014(CH 2 ) n NH 2 , \u2014(CH 2 ) n CN, halogen, C 1-6  alkyl, \u2014(CH 2 ) n \u2014C(\u2550O)OH, \u2014(CH 2 ) n \u2014C(\u2550O)OC 1-4  alkyl, \u2014(CH 2 ) n \u2014OC 1-4  alkyl, \u2014(CH 2 ) n \u2014C 3-10  carbocycle substituted with 0-5 R e , \u2014(CH 2 ) n -4- to 10-membered heterocycle substituted with 0-5 R e , and \u2014(CH 2 ) n -4- to 10-membered heterocycle substituted with 0-5 R e ; R 7  is independently selected from H, CN, OR b , halogen, NR a R a , and C 1-3  alkyl substituted with 0-5 R e ; R 8  is independently selected from H, OH, F, Cl, Br, C 1-4  alkyl, C 1-4  alkoxy, CF 3 , CN, C 3-6  cycloalkyl, aryl, and 5- to 6-membered heterocycle; R 10 , at each occurrence, is independently selected from H, halogen, CN, NO 2 , \u2550O, C(\u2550O)NR a R a , C(\u2550O)OR b , \u2014(CH 2 ) n \u2014OR b , \u2014(CH 2 ) n \u2014NR a R a , C(\u2550NOH)NH 2 , C 1-6  alkyl substituted with 0-5 R e , C 2-6  alkenyl substituted with 0-5 R e , C 2-6  alkynyl substituted with 0-5 R e , aryl substituted with 0-5 R e , \u2014(CH 2 ) n \u2014C 3-6  cycloalkyl substituted with 0-5 R e , \u2014(CH 2 ) n \u2014O-4- to 10-membered heterocyclyl substituted with 0-5 R e ; R a , at each occurrence, is independently selected from H, C 1-6  alkyl substituted with 0-5 R e , C 2-6  alkenyl substituted with 0-5 R e , C 2-6  alkynyl substituted with 0-5 R e , \u2014(CH 2 ) n \u2014C 3-10 carbocyclyl substituted with 0-5 R e , and \u2014(CH 2 ) n -heterocyclyl substituted with 0-5 R e ; or R a  and R a  together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R e ; R b , at each occurrence, is independently selected from H, C 1-6  alkyl substituted with 0-5 R e , C 2-6  alkenyl substituted with 0-5 R e , C 2-6  alkynyl substituted with 0-5 R e , \u2014(CH 2 ) n \u2014C 3-10 carbocyclyl substituted with 0-5 R e , and \u2014(CH 2 ) n -heterocyclyl substituted with 0-5 R e ; R c , at each occurrence, is independently selected from C 1-6  alkyl substituted with 0-5 R e , C 2-6 alkenyl substituted with 0-5 R e , C 2-6 alkynyl substituted with 0-5 R e , C 3-6 carbocyclyl, and heterocyclyl; R d , at each occurrence, is independently selected from H and C 1-4 alkyl substituted with 0-5 R e ; R e , at each occurrence, is independently selected from F, Cl, Br, CN, NO 2 , \u2550O, C 1-6  alkyl substituted with 0-5 R f , C 2-6  alkenyl, C 2-6  alkynyl, \u2014(CH 2 ) n \u2014C 3-6  cycloalkyl, \u2014(CH 2 ) n -aryl, \u2014(CH 2 ) n -heterocyclyl, CO 2 H, \u2014(CH 2 ) n OR f , SR f , and \u2014(CH 2 ) n NR f R f ; R f , at each occurrence, is independently selected from H, C 1-5  alkyl optionally substituted with F, Cl, Br, C 3-6  cycloalkyl, and phenyl, or R f  and R f  together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C 1-4 alkyl; n, at each occurrence, is an integer independently selected from 0, 1, 2, 3, and 4; and p, at each occurrence, is an integer independently selected from 0, 1, and 2.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.27778
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15115314', '15747818', '15750212', '15735322', '14942013']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.766204463304571
- 35 USC 102 Novelty (BERT): 0.5882715062380305
- Combined Prediction Score: 0.748411167597917
- Mean Citation Score: 394.471142
- Max Citation Score: 496.5713
- Similarity Product: 426.7913070605576

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test